Accelerate Diagnostics, Inc. (AXDX): Price and Financial Metrics

Accelerate Diagnostics, Inc. (AXDX): $4.10

0.07 (+1.74%)

POWR Rating

Component Grades














  • AXDX scores best on the Growth dimension, with a Growth rank ahead of 66.98% of US stocks.
  • The strongest trend for AXDX is in Sentiment, which has been heading up over the past 155 days.
  • AXDX's current lowest rank is in the Momentum metric (where it is better than 12.59% of US stocks).

AXDX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AXDX is -0.29 -- better than only 4.85% of US stocks.
  • AXDX's price/sales ratio is 24.26; that's higher than the P/S ratio of 92.68% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.51 for Accelerate Diagnostics Inc; that's greater than it is for just 4.37% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Accelerate Diagnostics Inc are VERI, COUP, DRIO, NVTA, and BSGM.
  • Visit AXDX's SEC page to see the company's official filings. To visit the company's web site, go to

AXDX Valuation Summary

  • AXDX's EV/EBIT ratio is -7.4; this is 125.26% lower than that of the median Healthcare stock.
  • AXDX's EV/EBIT ratio has moved down 1.9 over the prior 243 months.
  • Over the past 243 months, AXDX's price/sales ratio has gone up 16.5.

Below are key valuation metrics over time for AXDX.

Stock Date P/S P/B P/E EV/EBIT
AXDX 2021-08-31 32.0 -5.5 -4.6 -7.4
AXDX 2021-08-30 31.8 -5.5 -4.6 -7.3
AXDX 2021-08-27 31.9 -5.5 -4.6 -7.4
AXDX 2021-08-26 31.0 -5.3 -4.5 -7.2
AXDX 2021-08-25 32.1 -5.5 -4.6 -7.4
AXDX 2021-08-24 33.3 -5.7 -4.8 -7.6

AXDX Growth Metrics

    Its 5 year cash and equivalents growth rate is now at -45.18%.
  • Its year over year net cashflow from operations growth rate is now at 26.58%.
  • Its 4 year net income to common stockholders growth rate is now at -62.35%.
AXDX's revenue has moved up $1,339,000 over the prior 15 months.

The table below shows AXDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 11.547 -45.719 -73.811
2021-06-30 12.013 -45.927 -83.582
2021-03-31 11.34 -46.172 -81.138
2020-12-31 11.165 -50.394 -78.208
2020-09-30 11.525 -53.916 -80.631
2020-06-30 10.208 -58.627 -82.308

AXDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AXDX has a Quality Grade of D, ranking ahead of 23.75% of graded US stocks.
  • AXDX's asset turnover comes in at 0.125 -- ranking 68th of 75 Measuring and Control Equipment stocks.
  • AATC, TMO, and BMI are the stocks whose asset turnover ratios are most correlated with AXDX.

The table below shows AXDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.125 0.366 -0.333
2021-03-31 0.112 0.379 -0.320
2020-12-31 0.103 0.399 -0.302
2020-09-30 0.097 0.418 -0.316
2020-06-30 0.079 0.458 -0.343
2020-03-31 0.071 0.467 -0.358

AXDX Price Target

For more insight on analysts targets of AXDX, see our AXDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.7 (Moderate Buy)

AXDX Stock Price Chart Interactive Chart >

Price chart for AXDX

AXDX Price/Volume Stats

Current price $4.10 52-week high $15.60
Prev. close $4.03 52-week low $3.79
Day low $3.79 Volume 471,600
Day high $4.12 Avg. volume 285,900
50-day MA $5.12 Dividend yield N/A
200-day MA $6.55 Market Cap 252.15M

Accelerate Diagnostics, Inc. (AXDX) Company Bio

Accelerate Diagnostics is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company was founded in 1982 and is based in Tucson, Arizona.

AXDX Latest News Stream

Event/Time News Detail
Loading, please wait...

AXDX Latest Social Stream

Loading social stream, please wait...

View Full AXDX Social Stream

Latest AXDX News From Around the Web

Below are the latest news stories about Accelerate Diagnostics Inc that investors may wish to consider to help them evaluate AXDX as an investment opportunity.

Accelerate Diagnostics Announces Preliminary Fourth Quarter & Full-Year 2021 Financial Results

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the quarter and year ending December 31, 2021. Highlights for the fourth quarter and full-year 2021 are presented below.

Yahoo | January 13, 2022

Accelerate Diagnostics Wins Suzhou Innovation Award to Support Continued China Commercialization Efforts

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that it was honored as a recipient of China's Suzhou Industrial Park's (SIP) 15th Science and Technology Leaders Innovation Award for the Company's Accelerate Pheno® System.

Yahoo | January 12, 2022

Accelerate Diagnostics to Participate Virtually in 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that the company is scheduled to present at the 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022, at 9:45a.m. Eastern.

Yahoo | December 29, 2021

Accelerate Diagnostics (NASDAQ:AXDX) Upgraded to Hold at Zacks Investment Research

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report released on Wednesday, reports. According to Zacks, Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, []

Dakota Financial News | December 15, 2021

Contrasting Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX)

Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership. Institutional & Insider Ownership 71.3% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, [] The post Contrasting Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX) appeared first on ETF Daily News .

ETF Daily News | December 13, 2021

Read More 'AXDX' Stories Here

AXDX Price Returns

1-mo -18.00%
3-mo -35.74%
6-mo -40.23%
1-year -55.58%
3-year -74.85%
5-year -81.24%
YTD -21.46%
2021 -31.13%
2020 -55.15%
2019 46.96%
2018 -56.11%
2017 26.27%

Continue Researching AXDX

Want to see what other sources are saying about Accelerate Diagnostics Inc's financials and stock price? Try the links below:

Accelerate Diagnostics Inc (AXDX) Stock Price | Nasdaq
Accelerate Diagnostics Inc (AXDX) Stock Quote, History and News - Yahoo Finance
Accelerate Diagnostics Inc (AXDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8066 seconds.